Assay Range | 62.5--4000 pg/mL |
Sensitivity | 10.0 pg/mL |
Size | 96T |
Storage | Store at 2 - 8ºC. Keep reconstituted standard and detection Ab at -20 ºC |
Assay Principle | Sandwich ELISA |
Sample volume | 100 µL final volume, dilution factor varies on samples |
Detection Method | Chromogenic |
Kit Components
1. Recombinant Human CXCL11 standard: 2 vials
2. One 96-well plate precoated with anti-Human CXCL11 Ab
3. Sample diluent buffer: 12 mL - 1
4. Detection antibody: 130 µL, dilution 1:100
5. Streptavidin-HRP: 130 µL, dilution 1:100
6. Antibody diluent buffer: 12 mL x1
7. Streptavidin-HRP diluent buffer: 12 mL x1
8. TMB developing agent: 10 mL x1
9. Stop solution: 10 mL x1.
10. Washing solution (20x): 25 mL x1.
Background
Chemokine (C-X-C motif) ligand 11 (CXCL11), also known as Beta-R1, H174, interferon gamma-inducible protein 9 (IP-9), interferon-inducible T-cell alpha chemoattractant (I-TAC), small-inducible cytokine B11, is a small cytokine belonging to the CXC chemokine family. CXCL11 is synthesized as a 94 amino acid (aa) residue precursor protein with a 21 aa residue putative signal sequence and a 73 aa mature protein. CXCL11 is 36% and 37% aa identical to the other non-ELR CXC chemokines CXCL9 and CXCL10, respectively. Human CXCL11 exhibits 68% aa sequence homology with mouse CXCL11.
Expression of CXCL11 can be induced in astrocytes and monocytes, bronchial epithelial cells, intestinal epithelial cells, endothelial cells, keratinocytes, macrophages, and neutrophils in response to IFN-γ and is dramatically enhanced by addition of IL-1β or TNF-α. CXCL11 expression, however, is suppressed by the Th2 cytokines IL-4 and IL-10 and peroxisome proliferator-activated receptor γ activators. The chemokine receptor 3 (CXCR3) is the sole receptor for CXCL11. CXCL9 and CXCL10 also bind CXCR3, but with lower affinity and less potency than CXCL11. Primarily, CXCL11 exhibits chemotactic for interleukin-activated T-cells. Clinically, it has been implicated in allergic contact dermatitis, atherosclerosis, mycosis fungoides, and immune-mediated disorders of the central nervous system such as multiple sclerosis.